Palisade Bio, Inc. (PALI)

Over the past six months, Palisade Bio's stock price has experienced notable fluctuations, including a 40.40% decrease in the past month. Key events impacting the stock include missing Q3 2025 earnings per share estimates, analyst rating changes from various firms, closing a public offering generating approximately $138 million in gross proceeds, and positive insider sentiment driven by high-impact open-market purchases from insiders.

Demand for Palisade Bio's products and services is not subject to typical seasonal fluctuations. Instead, demand is driven by the progression of its clinical trials, regulatory approvals, and the prevalence of the diseases it aims to treat. Therefore, demand seasonality is not a relevant factor for Palisade Bio, Inc.

Palisade Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing oral therapies for gastrointestinal complications, autoimmune, inflammatory, and fibrotic diseases. Its primary product candidates include PALI-2108, a prodrug PDE4 inhibitor in Phase 1a/b clinical trials for ulcerative colitis and Phase 1a clinical trials for fibrostenotic Crohn's disease, PALI-1908, a therapeutic candidate under research for inflammatory bowel disease, and LB1148, an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize potent digestive proteases released from the gut following surgery.

Palisade Bio, Inc. is headquartered in Carlsbad, California, United States. Specific details regarding its broader operational or market geographic footprint beyond this location are not extensively detailed in the provided information.

Palisade Bio's brand reputation is influenced by its clinical-stage nature and financial performance. Analyst ratings are mixed but lean towards a "Moderate Buy" or "Strong Buy" consensus, with an average price target suggesting significant upside. However, the company faces financial challenges, including a lack of commercial infrastructure and unprofitability, leading to doubts about its ability to continue as a going concern. The recent downgrade by Wall Street Zen to a "sell" rating also reflects some negative sentiment.

Palisade Bio, Inc. has a concentrated ownership structure, with insiders holding a significant 90.65% of the company. Richard Garr is the largest individual shareholder, controlling 21.78% of the shares. Institutional investors also hold a substantial portion of the company's shares, with major shareholders including Vanguard Group Inc., UBS Group AG, and Perceptive Advisors LLC.